Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The New York Times – Business:

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Bancel, Stephane, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Health and Human Services Department, Kennedy, Robert F Jr, Merck & Company Inc, Moderna Inc, Trump, Donald J, Vaccination and Immunization
←Can We Do Anything About Tick-Borne Diseases Like Alpha-Gal Syndrome?
How Usher Gets Ready for a Show→

More posts

  • Peltola to reschedule Fairbanks, Bethel campaign stops after car crash

  • U.S. measles cases more than double what they were last year as outbreak spreads

  • Israeli president vows he will not bow to Trump in Netanyahu’s election fate

  • Try Guys’ Ned Fulmer Slams Ethan Klein’s Alleged Affair After He Criticized His Own Infidelity

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube